For its part, Eli Lilly told Medscape Medical News that the company hasn’t raised the list prices of its four insulin products in 7 ... a competitor’s basal insulin (Lantus), at a 78% lower ...

Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris' Semglee and Eli ... of their older products and the ...

Today, anyone using Lilly insulin and enrolled in one of its programs – regardless of their insurance status – is eligible to purchase their monthly prescription for $35. Through the Lilly ...

compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in hospitalized general medical patients with type 2 diabetes. The prospective ...